International Journal of Molecular Medical Science, 2024, Vol.14, No.1, 69-79 http://medscipublisher.com/index.php/ijmms 77 important insights into the role of genetics in dyslipidemia and cardiovascular disease. These technologies can help scientists better process and analyze large amounts of genomic data, uncover more genetic information and potential value. By constructing predictive models and optimizing algorithms, the accuracy and reliability of genomics in cardiovascular disease prevention can be improved. The integration of genomics with other omics such as transcriptomics and proteomics will also become an important direction in the future. Through the joint analysis of multiple omics data, a more comprehensive understanding of the pathogenesis and pathological processes of cardiovascular diseases can be obtained, providing deeper insights for the development of new treatment methods and drugs. With the increasing application of genomics in the prevention of cardiovascular diseases, it is also necessary to pay attention to its impact on society and economy. Pasipoularides (2018) suggests that genomics may change the understanding and treatment of cardiovascular diseases, promoting personalized and precise healthcare services. At the same time, the development of genomics may also bring about ethical, privacy, and legal issues that require us to formulate corresponding norms and policies for management and guidance. 4 Suggestions and Outlook Genomics plays an important role in the prevention of cardiovascular diseases. By utilizing advanced genomic technologies, individuals can more accurately assess their cardiovascular disease risk, providing strong support for developing personalized prevention strategies (Benes et al., 2018). In addition, genomics can guide personalized drug selection and dosage adjustment, as well as lifestyle interventions, in order to more effectively reduce the risk of cardiovascular disease. In the process of using genomics for cardiovascular disease prevention, it is also necessary to face relevant ethical, privacy, and legal issues, as well as technological challenges and limitations. These issues require continuous research and exploration by scientists, establishing corresponding norms and mechanisms to ensure the safe, effective, and widespread application of genomics in cardiovascular disease prevention. With the continuous progress and innovation of technology, the application prospects of genomics in the prevention of cardiovascular diseases are very broad. In the future, we can look forward to more efficient, accurate, and low-cost genome sequencing technology, as well as more advanced data analysis methods and algorithms, to provide more precise and personalized support for early screening, diagnosis, and prevention of cardiovascular diseases. In addition, multi omics integration research will become an important direction in the future. Through the joint analysis of multi omics data, a more comprehensive understanding of the pathogenesis and pathological processes of cardiovascular diseases can be obtained (Joshi et al., 2020), providing deeper insights for the development of new treatment methods and drugs. At the same time, it is necessary to pay attention to the social and economic impact of genomics in the prevention of cardiovascular diseases, formulate corresponding policies and norms, and ensure that it makes greater contributions to the healthy development of society and humanity. In summary, genomics has enormous potential and value in the prevention of cardiovascular diseases. Through continuous research and innovation, it is expected to better utilize genomics to prevent and treat cardiovascular diseases, and make greater contributions to the development of human health. References Abraham G., Rutten-Jacobs L., and Inouye M., 2021, Risk prediction using polygenic risk scores for prevention of stroke and other cardiovascular diseases, Stroke, 52: 2983-2991. https://doi.org/10.1161/STROKEAHA.120.032619 PMid:34399584 PMCid:PMC7611731 Abraham G., Havulinna A., Bhalala O., Byars S., Livera A., Yetukuri L., Tikkanen E., Perola M., Schunkert H., Sijbrands E., Palotie A., Samani N., Salomaa V., Ripatti S., and Inouye M., 2016， Genomic prediction of coronary heart disease，European Heart Journal, 37: 3267-3278. https://doi.org/10.1093/eurheartj/ehw450 PMid:27655226 PMCid:PMC5146693
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==